Post Reply
4321-4340 of 10899
A bit disappointed to see price drop despite good leaders trial results though.......
Congrats, I'm together with you all the way. My avg much lower, but want to stay on for a chance to see new highs being set this year, that is if we are in great luck. Huat arh..........everyone vested.
TP of FV 74cts. Good blessing loh.
Got it at 57.3 cts avg. Ha ha, 8 cts away liao. No harm to wait for another 8 cts loh. Huat huat.
keepnosecrets ( Date: 23-Sep-2009 20:50) Posted:
The immediate TP is fair value 74 cents which many of you would not want to go in because now 66 cents, only 8 cents away leh. So if you are in, you should only be prepared for holding a little longer ya?. Understand your own financial position. Would you like 5 to 8 cents profit? You can get it for many other counters and faster too.
But don't underestimate Biosensors for its spiking power. My chart shows it is very strong and will take us by surprise going to where it has not gone before since quite a while oredi. DYO HAM YOD BOS!!! (Do your own homework and make your own decision buy or sell.) |
|
LEADERS Two-Year Results Indicate Improved Safety and Efficacy of Biodegradable Polymer Technology over Conventional Durable Polymers
San Francisco, USA, 23 September 2009 – Biosensors International Group, Ltd (“Biosensors”, “Company”, BIG:SP) today announced the two-year results of the LEADERS trial, which showed an increasing trend towards a safety benefit for the Biosensors Biolimus A9™-eluting stent with abluminal biodegradable polymer (“BES”) compared to Johnson & Johnson’s sirolimus-eluting stent with a durable polymer (“SES”). Results were presented by Professor Volker Klauss as part of the Late Breaking Trial session at the 21st annual Transcatheter Cardiovascular Therapeutics (“TCT”) scientific symposium, sponsored by the Cardiovascular Research Foundation.
“These additional follow-up results from LEADERS confirm that the Biosensors Biolimus A9-eluting stent is safe and effective two years after implantation in an all-comers population reflecting patients we treat in our routine clinical practice”, commented LEADERS Principal Investigator Professor Stephan Windecker, University Hospital, Bern, Switzerland.
In the overall study population there were similar outcomes for BES and SES, with an increasing advantage observed for BES in both Major Adverse Cardiac Events (“MACE”) (BES: 13% vs. SES: 15.4% p=0.18) and Cardiac Death/Myocardial Infarction (BES: 8.3% vs. SES: 9.1% p=0.59) compared with both nine and 12-month results. The differences were not statistically significant. In the high risk sub-group of STEMI patients (ST Elevation Myocardial Infarction), a statistically significant improved MACE rate was demonstrated with BES compared to SES (8.1% vs. 19.3% p<0.01).
Although this was an all-comers study, occurrence of very late stent thrombosis events was rare (BES 0.2% vs. SES 0.5% p=0.73). In the BES group, the two events observed were limited to patients with Saphenous Vein Grafts (“SVG”), who are traditionally excluded from drug-eluting stent trials. Notably, there were no very late stent thrombosis events in BES patients after discontinuation of dual anti-platelet therapy (“DAPT”).
“We are extremely pleased with these long-term results”, concluded Michael Kleine, President & CEO of Biosensors. “They confirm that our drug-eluting stent technology, with its unique combination of anti-restenotic drug and abluminal biodegradable polymer, has created a new industry standard.”
LEADERS (Limus Eluted from A Durable versus ERodable Stent coating), is a multi-centre randomized study in which 1,707 patients eligible for PCI for symptomatic coronary disease received either a Biosensors Biolimus A9™-eluting stent with an abluminal biodegradable polymer coating, or a sirolimus-eluting stent with a durable polymer. Inclusion criteria were broad, reflecting routine clinical practice, without limitations regarding type of coronary vessel, lesion length or number of treated lesions. The nine-month results, presented at the European Society of Cardiology (“ESC”) congress in 2008 and simultaneously published in The Lancet, demonstrated BES to be non-inferior to SES in respect of the primary endpoint, incidence of MACE at nine months. This non-inferiority was confirmed in the 12-month results, at which time a non-significant difference in the rates of stent thrombosis in favor of BES was also observed.
Although funded by Biosensors, LEADERS was independently designed, implemented and analyzed by the study investigators. Moreover, data management and analysis were performed by an independent academic institution.
The immediate TP is fair value 74 cents which many of you would not want to go in because now 66 cents, only 8 cents away leh. So if you are in, you should only be prepared for holding a little longer ya?. Understand your own financial position. Would you like 5 to 8 cents profit? You can get it for many other counters and faster too.
But don't underestimate Biosensors for its spiking power. My chart shows it is very strong and will take us by surprise going to where it has not gone before since quite a while oredi. DYO HAM YOD BOS!!! (Do your own homework and make your own decision buy or sell.)
| meatball wrote: |
Biosensor confirm MULTI BaGGER in the long term. 
Cheers  |
..1 lot buy up to create new 2009's high of 66cts
16:59:05 0.655 50,000 B
16:58:56 0.660 1,000 A 
:P
16:58:44 0.655 125,000 A
16:57:45 0.655 20,000 A
16:57:42 0.655 30,000 A
16:57:37 0.655 20,000 A
16:57:19 0.655 5,000 B
16:57:06 0.655 25,000 A
16:56:54 0.655 30,000 A
16:56:40 0.655 20,000 B
16:56:20 0.655 20,000 B
16:56:19 0.655 50,000 B
16:56:09 0.655 10,000 B
16:55:15 0.655 5,000 A
16:55:11 0.655 1,000 A
16:54:52 0.655 10,000 A
16:54:44 0.655 4,000 A
16:54:31 0.655 16,000 A
16:54:19 0.655 200,000 A
16:52:51 0.655 30,000 A
16:51:48 0.655 9,000 B
16:51:40 0.655 20,000 B
16:51:13 0.655 10,000 B
16:51:05 0.655 5,000 B
16:50:55 0.655 10,000 B
16:50:45 0.655 12,000 A
16:50:21 0.655 38,000 B
16:50:18 0.655 10,000 B
16:50:09 0.655 182,000 A
16:50:02 0.655 100,000 A
16:49:39 0.655 15,000 A
16:49:37 0.655 13,000 A
16:49:36 0.655 9,000 A
16:49:35 0.655 180,000 A
16:49:10 0.655 20,000 A
16:49:01 0.655 50,000 A
16:49:00 0.655 100,000 A
16:48:56 0.655 30,000 A
16:48:28 0.655 50,000 A
16:47:52 0.655 10,000 A
16:46:49 0.655 100,000 A
16:46:29 0.655 23,000 A
16:45:07 0.650 20,000 B
16:44:49 0.655 1,000 A
16:44:47 0.655 10,000 A
16:44:21 0.655 50,000 A
16:42:37 0.650 100,000 B
16:40:29 0.655 10,000 A
16:39:05 0.655 50,000 A
16:38:08 0.650 20,000 B
16:38:04 0.655 500,000 A
16:37:17 0.650 8,000 A
16:36:43 0.650 50,000 A
16:36:34 0.650 50,000 A
16:36:19 0.650 10,000 A
16:35:41 0.650 20,000 A
16:34:37 0.650 15,000 A
16:34:16 0.650 1,000 A
16:33:28 0.650 2,000 A
16:32:58 0.650 10,000 A
16:31:44 0.650 30,000 A
16:31:38 0.650 300,000 A
16:29:13 0.650 50,000 A
16:29:10 0.650 1,000 A
16:28:22 0.650 50,000 A
16:28:20 0.650 100,000 A
16:27:03 0.650 50,000
Ref to DIG making $ on Citi Grp:
AK dun ask people to buy stock, but ds burger got potential. AK view only. 2Y apply. Mood good loh, as Gent SP cheong.
keepnosecrets ( Date: 23-Sep-2009 08:34) Posted:
| Biosensors is chartists' baby, breaking out, up and up. Missed the 62 cents recently. Waited in queue but did not get. Will plough some profits into this. |
|
Biosensors is chartists' baby, breaking out, up and up. Missed the 62 cents recently. Waited in queue but did not get. Will plough some profits into this.
| Tue Sep 22, 2009 11:19 pm Post subject: |
   |
|
Looks > promising,around 3.48pm today hit 2009's high of 65cts
17:05:03 0.640 310,000 B
16:58:56 0.640 13,000 B
16:57:11 0.645 1,000 A
16:53:15 0.645 15,000 A
16:52:33 0.645 30,000 A
16:45:53 0.645 5,000 A
16:45:52 0.645 5,000 A
16:41:17 0.645 50,000 A
16:36:46 0.645 10,000 A
16:32:59 0.645 40,000 A
16:25:32 0.645 30,000 A
16:23:03 0.645 2,000 A
16:22:12 0.645 50,000 A
16:21:56 0.645 50,000 A
16:21:35 0.645 30,000 A
16:20:13 0.645 10,000 A
16:19:38 0.645 2,000 A
16:18:51 0.645 5,000 A
16:18:23 0.645 15,000 A
16:17:31 0.645 30,000 A
16:17:16 0.645 45,000 B
16:16:50 0.645 18,000 A
16:16:36 0.645 15,000 A
16:16:33 0.645 30,000 A
16:15:12 0.645 1,000 A
16:14:38 0.645 136,000 B
16:12:59 0.645 64,000 A
16:12:55 0.645 136,000 B
16:12:15 0.645 30,000 B
16:11:58 0.645 50,000 B
16:11:56 0.645 134,000 A
16:10:47 0.645 36,000 B
16:09:26 0.645 4,000 A
16:09:14 0.645 20,000 A
16:09:03 0.645 10,000 A
16:08:45 0.645 476,000 B
16:07:22 0.650 10,000 A
16:05:19 0.650 10,000 A
16:03:55 0.650 5,000 A
16:02:19 0.645 10,000 B
16:01:08 0.645 100,000 B
16:00:47 0.645 9,000 B
16:00:46 0.650 200,000 A
16:00:32 0.645 20,000 B
15:59:37 0.645 11,000 B
15:57:59 0.650 10,000 A
15:57:27 0.650 20,000 A
15:57:04 0.645 10,000 B
15:56:54 0.645 10,000 B
15:56:22 0.645 50,000 B
15:56:01 0.645 20,000 B
15:55:13 0.645 20,000 B
15:55:12 0.645 100,000 B
15:54:34 0.645 15,000 B
15:53:29 0.645 10,000 B
15:53:29 0.645 10,000 B
15:52:52 0.645 200,000 B
15:50:56 0.645 50,000 B
15:50:52 0.650 5,000 A
15:48:22 0.650 5,000 A
15:47:55 0.645 15,000 B
15:46:43 0.645 60,000 B
15:46:29 0.645 100,000 B
15:45:36 0.645 20,000 B
15:44:06 0.645 4,000 A
15:43:57 0.645 1,000 B
15:43:00 0.645 50,000 B
15:42:30 0.645 16,000 B
15:42:29 0.645 20,000 A
15:42:25 0.645 10,000 A
15:42:24 0.645 30,000 A
15:42:20 0.645 10,000 A
15:42:06 0.645 40,000 A
15:41:59 0.645 15,000 A
15:41:41 0.645 138,000 B
15:41:39 0.645 162,000 B
15:41:24 0.645 50,000 B
15:38:42 0.650 500,000 A
15:38:31 0.645 10,000 B
15:37:51 0.645 20,000 B
15:37:48 0.645 10,000 B
15:37:18 0.645 200,000 B
15:36:35 0.645 178,000 B
15:36:28 0.645 110,000 B
15:36:13 0.650 100,000 A
15:36:03 0.650 31,000 A
15:36:00 0.650 30,000 A
15:35:59 0.650 300,000 A
15:35:59 0.650 50,000 A
15:35:40 0.650 40,000 A
15:35:32 0.650 100,000 A
15:35:08 0.645 100,000 B
15:34:58 0.645 20,000 B
15:34:55 0.645 70,000 A
15:34:54 0.645 35,000 A
15:34:53 0.645 20,000 A
15:34:51 0.645 10,000 A
15:34:50 0.645 30,000 A
15:34:48 0.645 100,000 A
15:34:46 0.645 |
But mermaid, genting swept past Big, to win by many cents.
keepnosecrets ( Date: 22-Sep-2009 15:36) Posted:
| Round the home turn, look at Biosensors flying!! |
|
Round the home turn, look at Biosensors flying!!
Drug-Eluting Stents Safe, Effective for Treatment of Chronic Total Occlusions
Monday, September 21, 2009
SAN
FRANCISCO, CA – A multicenter study in Asia found drug-eluting stents
effective with a low rate of acute complications in patients with
chronic total occlusions (CTOs) undergoing PCI. Results of the study
will be presented at the 21st annual Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium, sponsored by the
Cardiovascular Research Foundation (CRF).
The aim of the study, “Drug-Eluting Stents for the Treatment of
Chronic Total Occlusion: A Comparison with Sirolimus (SES), Paclitaxel
(PES), Zotarolimus (ZES), Biolimus A9 (BES), EPC Capture (ECS) and
Everolimus-Eluting Stent (EES): Multicenter Registry in Asia” is to
compare the safety and efficacy of SES, PES, ZES, BES, SCS and EES in
the treatment of patients with chronic total occlusion (blockage) of
cardiac blood vessels. The study will be presented as a poster abstract
(TCT-234) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in
Hall D of The Moscone Center.
For the study, researchers led by Sunao Nakamura, MD, performed a
prospective analysis of 1,148 patients with 1,253 CTOs treated with
different drug-eluting stents (396 SES, 526 PES, 177 ZES, 66 BES, 41
ECS, and 43 EES) in six high volume Asian centers after successful CTO
re-canalization was performed.
Dr. Nakamura, who will report on the results of the investigations,
is Vice President and Director of the Cardiovascular Center at New
Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto
University in Matsudo, Japan.
The researchers found that the incidence of major adverse cardiac
events (MACE) at 30 days was nearly non-existent in patients with CTO
lesions treated with drug-eluting stents (0.4% in patients with PES,
0.6% in ZES and 0% in all other categories). MACE at 9 months was 3.6%
for those receiving SES, 6.7% for PES, 10.4% for ZES, 4.5% for BES,
10.3% for ECS and 2.4% for EES. Target lesion revascularization (TLR)
at 9 months was 3.6% for patients who received SES, 6.7% for PES, 10.4%
for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES.
In addition, patients treated with SES, BES and EES showed a lesser
rate of angiographic restenosis compared with other drug-eluting stents
at 9 months (4.0% restenosis for patients receiving SES, 6.7% for PES,
12.3% for ZES, 4.5% for BES, 10.3% for ECS and 2.4% for EES).
In conclusion, Dr. Nakamura noted that, “The study indicates a good clinical performance of the new BES and EES devices.”
The research team for the study also included Shotaro Nakamura, MD,
New Tokyo Hospital; Hisao Ogawa, MD, Kumamoto University Hospital,
Kumamoto, Japan; Jang-Ho Bae, MD, Konyang University Hospital, Daejeon,
Republic of Korea; Yeo Hans Cahyadi, MD, Husada Hospital, Jakarta,
Indonesia; Wasan Udayachalerm, MD, King Chulalongkorn Memorial
Hospital, Bangkok, Thailand; Damras Tresukosol, MD, Her Majesty's
Cardiac Center Siriraj Hospital, Bangkok, Thailand; and Sudaratana
Tansuphaswadikul, MD, Chest Disease Institute, Bangkok, Thailand.
Source: The Cardiovascular Research Foundation
Researchers Find Drug-Eluting Stents Safe, Effective for PCI in Diabetics
Monday, September 21, 2009
SAN
FRANCISCO, CA ─ Results of a multicenter study in Asia, demonstrating
that drug-eluting stents are effective with a low rate of complications
in diabetic patients, will be presented at the 21st annual
Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium,
sponsored by the Cardiovascular Research Foundation (CRF).
The study, “The Effect of Drug-Eluting Stents on Clinical and
Angiographic Outcomes in Diabetic Patients: Multicenter Registry in
Asia,” compared the safety and efficacy of sirolimus (SES), paclitaxel
(PES), zotarolimus ( ZES), biolimus A9 (BES) and everolimus-eluting
(EES) stents on the outcome of percutaneous coronary intervention (PCI)
in patients with diabetes mellitus (DM).
The study will be presented as a poster abstract (TCT-363) on
Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The
Moscone Center. Sunao Nakamura, MD, lead investigator for the study,
will report on the results of the investigations. Dr. Nakamura is Vice
President and Director of the Cardiovascular Center at New Tokyo
Hospital as well as Clinical and Visiting Professor of Kumamoto
University in Matsudo, Japan.
The investigation consisted of a prospective analysis of 1,373
patients with DM treated with different drug-eluting stents (508 SES,
420 PES, 204 ZES, 120 BES and 121 EES) in six high-volume Asian
centers. The study endpoints were the incidence of MACE at 30 days, the
restenosis rate at 9 months and target lesion revascularization (TLR)
at 9 months.
The incidence of MACE with this study cohort was 0.8% in patients
receiving SES, 1.2% in PES, 1.0% in ZES, 0.8% in BES and 0.0% in EES.
The restenosis rate at 9 months was 7.9% for those receiving SES, 12.6%
for PES, 16.2% for ZES, 5.0% for BES and 6.7% for EES. TLR at 9 months
was 6.5% in patients receiving SES, 10.7% with PES, 13.7% with ZES,
5.0% with BES and 4.1% with EES.
The researchers concluded that the use of drug-eluting stents in
patients with DM was safe with low acute complications. Further,
patients treated with SES, BES and EES showed a lesser rate of
restenosis when compared with other drug-eluting stents.
The research team for the study also included Shotaro Nakamura, MD,
New Tokyo Hospital; Hisao Ogawa, MD, Kumamoto University Hospital,
Kumamoto, Japan; Jang-Ho Bae, MD, Konyang University Hospital, Daejeon,
Republic of Korea; Yeo Hans Cahyadi, MD, Husada Hospital, Jakarta,
Indonesia; Wasan Udayachalerm, MD, King Chulalongkorn Memorial
Hospital, Bangkok, Thailand; Damras Tresukosol, MD, Her Majesty's
Cardiac Center Siriraj Hospital, Bangkok, Thailand; and Sudaratana
Tansuphaswadikul, MD, Chest Disease Institute, Bangkok, Thailand.
Source: The Cardiovascular Research Foundation
I Ot two months first =X
cn up sure can down,,,,,,,,,,,,,,let the dust settle first,,,,,,,,,,,,,,,,,,,,,storm havent come,,,,,,,,,,,,,,,,may be soon,,,,,,,,,,,,,,,,,bukit timah hill three week
Thanks for the divine blessings.
starlene ( Date: 13-Sep-2009 19:23) Posted:
|
Long term investors of BIG will be blessed.
http://img147.imageshack.us/i/img2900.jpg/
keepnosecrets ( Date: 09-Sep-2009 16:50) Posted:
| Think 74 cents Fair value is just a modest estimate. |
|
Think 74 cents Fair value is just a modest estimate.
Biosensors International Group: Positive industry outlook. Maintain BUY.
Improving industry prospects
industry has yielded encouraging results. DES usage has risen to the
mid-70% range (vs ~65% year ago). While there are still proponents and
opponents to DES usage, rising clinical usage indicate that practitioners
are more comfortable with the significant research put in for the last three
years. Even less sanguine opponents of DES usage like Dr Edoardo
Camenzind* said to "resist short-term (marketing) distractions and stick
with (products with good) medical evidence". Biosensors possesses positive
"medical evidence" and we expect its next update in end Sep 09 at a
clinical conference to be encouraging.
. Our scan of the Drug Eluting Stent (DES)
Peer group scan.
has been gaining market share. Along with Boston Scientifics' Promus
DES (sub-licensed Abbott DES platform), market watchers estimate that
the
lose market share with its older
with its
platform is estimated to command market share in the mid-teens. The
battle continues to be intense but the trend for technological superiority is
sustained. We believe that the current iteration for clinicians to stick to
products with strong clinical data will bode well for Biosensors' BioMatrix
DES which is authenticated by strong clinical data.
Abbott's Xience V DES is now the key product thatXience V platform has >50% market share in the US. JnJ continues toCypher DES but is hoping to roar backNevo DES (but likely only in 2010). Medtronic's Endeavour DES
Pricing pressure not for premium products
webcasts indicate that ASP pricing pressures for DES have come more
from hospitals vs. peers engaging in a price undercutting war. Abbott's
management indicated that its newer generation Xience V DES have been
sustaining ASPs. Our previous checks with Biosensors indicate that ASPs
have been holding up in the EU markets.
. Abbott's and JnJ's 2Q
M&A exit.
M&A situation. Adequate intellectual property protection, superior
technology and a well-executed product launch has catapulted Biosensors
onto the radar screens of the big boys. However, we think the company
may need significantly more cash and people bandwidth to sustain its
growth trajectory past FY11F. Our bets for future acquirers are Medtronic
(lagging technology pipeline) and Terumo (Asian based powerhouse and
current Biosensors' licensee). Maintain
We still believe a key exit for long-term investors will be anBUY at S$0.74 fair value.
from OCBC research
Biosensors International Group: Positive industry outlook. Maintain BUY.
Summary: Our scan of the Drug Eluting Stent (DES) industry has yielded encouraging results. DES usage has risen to the mid-70% range (vs. ~65% year ago). While there are still proponents and opponents to DES usage, rising clinical usage indicate that practitioners are more comfortable with the significant research put in for the last three years. Our scan of Biosensors’ peer group revealed a tough battleground in the US DES market. Abbott’s technology continues to gain ground while Medtronic and JnJ struggle to keep up. Clinicians being advocated to “resist short-term distractions and stick with medical evidence” will bode well for Biosensors’ BioMatrix DES which is authenticated by strong clinical data. ASPs have largely held up well. We still believe a key exit for long-term investors will be an M&A situation and think the company may need significantly more cash and people bandwidth to sustain its growth trajectory past FY11F. Our bets for future acquirers are Medtronic (lagging technology pipeline) and Terumo (Asian-based powerhouse and current Biosensors’ licensee). Maintain BUY at S$0.74 fair value. See Exhibit 2 for our “blue-sky” M&A assumptions.
